论文部分内容阅读
目的:检测国人前列腺癌患者融合基因TMPRSS2:ERG的发生率以及该融合基因和ERG表达的关系。方法:连续选取经直肠B超前列腺癌穿刺证实的前列腺癌新鲜标本62例、6例高级别前列腺上皮内瘤(HGPIN)标本和9例其他器官恶性肿瘤细胞株,另选取10例BPH组织作为对照,采用RT-PCR检测融合基因,采用real-time RT-PCR检测ERG表达。结果:本组国人前列腺癌患者融合基因TMPRSS2:ERG的发生率为45.16%,融合基因TMPRSS2:ERG诊断前列腺癌的特异度为93.75%,灵敏度为45.16%。前列腺癌融合基因组ERG基因表达显著高于前列腺癌非融合基因组(t=3.549,P=0.001)。结论:融合基因TMPRSS2:ERG在本组国人前列腺癌患者中的发生率以及在HGPIN病灶的发生率与国外研究报道相似。该融合基因诊断前列腺癌的特异性很高,但灵敏度偏低。融合基因和前列腺癌组织中ERG高表达有关。
Objective: To detect the incidence of fusion gene TMPRSS2: ERG in Chinese patients with prostate cancer and the relationship between the fusion gene and ERG expression. Methods: Totally 62 fresh prostate cancer specimens, 6 HGPIN specimens and 9 other malignant tumor tissues confirmed by transrectal B-prostate cancer were selected. Ten BPH tissues were selected as the control The fusion gene was detected by RT-PCR and ERG expression was detected by real-time RT-PCR. Results: The incidence of fusion gene TMPRSS2: ERG was 45.16% in our group. The specificity of TMPRSS2: ERG in diagnosing prostate cancer was 93.75% and the sensitivity was 45.16%. ERG gene expression in prostate cancer fusion was significantly higher than that in prostate cancer non-fusion (t = 3.549, P = 0.001). Conclusion: The incidence of fusion gene TMPRSS2: ERG in this group of Chinese patients with prostate cancer and the incidence of HGPIN lesions are similar to those reported in foreign studies. The fusion gene diagnosis of prostate cancer is very specific, but the sensitivity is low. Fusion genes and prostate cancer tissue ERG high expression.